London-based multinational pharmaceutical company GSK has informed a local importer of medicines that it has decided to withdraw four of its drugs sold under the brand name Zantac from the local market, the Health Bureau (SSM) said in a statement on Tuesday.
According to the statement, the four drugs to be withdrawn from the market are Zantak Tablet 150mg, Zantac Tablet 300mg, Zantac Syrup 150mg/10ml, and Zantac Injection 25mg/ml.
According to recent international newswire reports, Zantac, which is made with the raw material “Ranitidine”, is a substance used for the treatment of stomach acidity and related discomforts. The US Food and Drug Administration (FDA) is reported to have recently warned that the medicine could cause cancer due to its possible carcinogenic impurity.
